Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2014 Jan 1;65(1):1-9.
doi: 10.1097/QAI.0b013e3182a1bc81.

Susceptibility to CD8 T-cell-mediated killing influences the reservoir of latently HIV-1-infected CD4 T cells

Affiliations

Susceptibility to CD8 T-cell-mediated killing influences the reservoir of latently HIV-1-infected CD4 T cells

Maria J Buzon et al. J Acquir Immune Defic Syndr. .

Abstract

Background: HIV-1 establishes a lifelong infection in the human body, but host factors that influence viral persistence remain poorly understood. Cell-intrinsic characteristics of CD4 T cells, the main target cells for HIV-1, may affect the composition of the latent viral reservoir by altering the susceptibility to CD8 T-cell-mediated killing.

Results: We observed that susceptibilities of CD4 T cells to CD8 T-cell-mediated killing, as determined in direct ex vivo assays, were significantly higher in persons with natural control of HIV-1 (elite controllers) than in individuals effectively treated with antiretroviral therapy. These differences were most pronounced in naive and in terminally differentiated CD4 T cells and corresponded to a reduced viral reservoir size in elite controllers. Interestingly, the highest susceptibility to CD8 T-cell-mediated killing and lowest reservoirs of cell-associated HIV-1 DNA was consistently observed in elite controllers expressing the protective HLA class I allele B57.

Conclusions: These data suggest that the functional responsiveness of host CD4 T cells to cytotoxic effects of HIV-1-specific CD8 T cells can contribute to shaping the structure and composition of the latently infected CD4 T-cell pool.

PubMed Disclaimer

Conflict of interest statement

None of the authors declare a conflict of interest related to this work.

Figures

Figure 1
Figure 1. Increased susceptibility of CD4 T cells from elite controllers to CD8 T cell-mediated killing
(A) Representative dot plots reflecting the proportions of Annexin V-positive CD4 T cells following exposure to A2-SL9-specific CD8 T cells, with or without prior pulsing of target cells with the epitopic peptide. Data from bulk CD4 T cells and indicated CD4 T cells subsets are shown. (B–C) Proportions of Annexin V-positive CD4 T cells from HIV-1 negative persons (Neg), HAART-treated subjects (HAART) or elite controllers (EC) after co-culture with identical immunodominant HIV-1-specific CD8 T cell populations (B), or without exposure to HIV-1-specific CD8 T cell clones (C). Left panels reflect data from all individuals in each study cohort, right panels indicated data from subgroups of patients expressing HLA-B57 or HLA-A2/HLA-B8. Significance was tested using Mann-Whitney U tests.
Figure 2
Figure 2. CD4 T cell subset-specific susceptibility to cytotoxic effects of HIV-1-specific CD8 T cells
(A): Proportions of Annexin V-positive CD4 T cells with naïve (NA), terminally-differentiated (TE), central-memory (CM) and effector-memory (EM) phenotype, after exposure to four different HIV-1-specific CD8 T cells. Data from all three study cohorts are included. (B–E): Susceptibility of naïve (B), central-memory (C), effector-memory (D) or terminally-differentiated CD4 T cells from the three study cohorts to HIV-1-specific CD8 T cells. Left panels indicate data from all individuals within each study group, middle panels indicate data stratified by expression of HLA-B57 vs. HLA-A2/B8. Significance was tested using Mann-Whitney U tests. Right panels indicate Spearman’s correlations between susceptibilities to CD8 T cell mediated killing and corresponding levels of immune activation in indicated CD4 T cell subsets.
Figure 3
Figure 3. Latent viral reservoirs in CD4 T cell subsets from elite controllers and HAART-treated patients
(A–B): Cell-associated HIV-1 DNA in total, naïve and memory CD4 T cells from all HAART-treated persons and elite controllers (A) and following stratification according to expression of HLA-B57 or expression of HLA-A2 or B8 (B). (A–B): Data from each patient are shown as individual symbols. The lower limit of detection with minimum input DNA of 20,000 cell equivalents was 1 copy/1 million cells. Data are not shown for samples with insufficient DNA. Significance was calculated using Mann-Whitney U tests. Orange symbols=HAART treated patients, blue symbols=elite controllers.
Figure 4
Figure 4. Latent viral reservoirs in naïve CD4 T cells are associated with susceptibilities to CD8 T cell-mediated killing
(A): Data reflect Spearman’s Correlations between susceptibility of indicated CD4 T cell populations to CD8 T cell mediated killing, and corresponding levels of cell-associated HIV-1 DNA. (B–C): Spearman’s correlation between magnitude of total (B) or Gag-specific (C) interferon-γ secreting HIV-1-specific CD8 T cells and corresponding levels of cell-associated HIV-1 DNA.

Similar articles

Cited by

References

    1. Trono D, Van Lint C, Rouzioux C, Verdin E, Barre-Sinoussi F, Chun TW, Chomont N. HIV persistence and the prospect of long-term drug-free remissions for HIV-infected individuals. Science. 2010;329:174–180. - PubMed
    1. Richman DD, Margolis DM, Delaney M, Greene WC, Hazuda D, Pomerantz RJ. The challenge of finding a cure for HIV infection. Science. 2009;323:1304–1307. - PubMed
    1. Chomont N, El-Far M, Ancuta P, Trautmann L, Procopio FA, Yassine-Diab B, et al. HIV reservoir size and persistence are driven by T cell survival and homeostatic proliferation. Nat Med. 2009;15:893–900. - PMC - PubMed
    1. Wightman F, Solomon A, Khoury G, Green JA, Gray L, Gorry PR, et al. Both CD31(+) and CD31(-) naive CD4(+) T cells are persistent HIV type 1-infected reservoirs in individuals receiving antiretroviral therapy. J Infect Dis. 2010;202:1738–1748. - PubMed
    1. Archin NM, Liberty AL, Kashuba AD, Choudhary SK, Kuruc JD, Crooks AM, et al. Administration of vorinostat disrupts HIV-1 latency in patients on antiretroviral therapy. Nature. 2012;487:482–485. - PMC - PubMed

Publication types